Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
25 mars 2019 00h00 HE | Dermira, Inc.
New multichannel consumer campaign will feature QBREXZA patientsCampaign to drive consumer awareness of QBREXZAQBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
22 mars 2019 16h01 HE | Dermira, Inc.
MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Prices $130.0 Million Public Offering of Common Stock
19 mars 2019 19h36 HE | Dermira, Inc.
MENLO PARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Proposed Public Offering of Common Stock
18 mars 2019 16h30 HE | Dermira, Inc.
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
18 mars 2019 07h00 HE | Dermira, Inc.
- All three doses of lebrikizumab met primary endpoint with statistical significance- Lebrikizumab was well-tolerated; safety profile consistent with prior studies- Efficacy and safety profile support...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present at the Cowen and Company 39th Annual Health Care Conference
05 mars 2019 16h00 HE | Dermira, Inc.
MENLO PARK, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Presents New Data from its Phase 3 Clinical Program Evaluating Glycopyrronium Tosylate (QBREXZA™ (glycopyrronium) cloth) in Patients with Primary Axillary Hyperhidrosis
01 mars 2019 08h00 HE | Dermira, Inc.
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary hyperhidrosis  New analysis from...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
26 févr. 2019 16h01 HE | Dermira, Inc.
QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for approximately 76% of...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present New Analyses of the Glycopyrronium Tosylate Clinical Program at the 77th American Academy of Dermatology Annual Meeting
26 févr. 2019 08h00 HE | Dermira, Inc.
MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
22 févr. 2019 08h00 HE | Dermira, Inc.
- Study will assess the impact of QBREXZA treatment on sweat severity in patients with primary palmar hyperhidrosis- Results will inform potential development plans for QBREXZA in primary palmar...